Transdermal Delivery of Human Growth Hormone Through RF-Microchannels
- 378 Downloads
To evaluate the bioavailability and bioactivity of human growth hormone (hGH) delivered transdermally through microchannels (MCs) in the skin created by radio-frequency (RF) ablation.
The creation of MCs was observed in magnified rat and guinea pig skin after staining by methylene blue. Various doses of hGH in a dry form were applied on rat or guinea pig (GP) skin after the formation of MCs. The pharmacokinetic profile of systemic hGH in both animal models was monitored for 15 h post patch application. Bioactivity of the transdermally delivered hGH was verified by measuring IGF-I levels in hypophysectomized rats.
The ordered array of MCs was clearly visible in the magnified rat and guinea pig skin. The MCs were very uniform in diameter and of equal separation. Creation of MCs in the outer layers of the skin enabled efficient delivery of hGH, with a bioavailability of 75% (rats) or 33% (GPs) relative to subcutaneous (s.c.) injection with plasma profiles resembling that of s.c. injection. Elevated levels of systemic insulin-like growth factor-1 (IGF-I) were observed after transdermal delivery of hGH to hypophysectomized rats indicative of the bioactivity of the transdermally delivered hGH in vivo.
Formation of RF-microchannels is a well-controlled process. These MCs permitted the transdermal delivery of bioactive hGH in rats and GPs with high bioavailability.
Key Words:transdermal drug delivery radio-frequency ablation Via Derm stratum corneum human growth hormone
Unable to display preview. Download preview PDF.
- 10.10. B. L. Silverman, S. L. Blethen, E. O. Reiter, K. M. Attie, R. B. Neuwirth, and K. M. Ford. A long-acting human growth hormone (Nutropin depot): efficacy and safety following two years of treatment in children with growth hormone deficiency. J. Pediatr. Endocrinol. Metab. 15:715–722 (2002).Google Scholar
- 11.11. International Patent Application WO 2004/039428. Transdermal delivery system for dried particulate or lyophilized medications, TransPharma Medical Ltd., Lod, Israel.Google Scholar
- 13.13. N. Kankikkannan. Iontophoresis-based transdermal delivery systems BioDrugs 16:339–347 (2002).Google Scholar
- 15.15. G. L. Grove, M. J. Grove, C. Zerweck, and E. Pierce. Comparative metrology of the evaporimeter and the Dermalab TEWL probe Skin Res. Technol. 5:1–8 (1999).Google Scholar
- 16.16. R. Panchagnula, K. Stemmer, and W. A. Ritschel. Animal models for transdermal delivery Meth. Find. Exp. Clin. Pharmacol. 19:335–341 (1997).Google Scholar
- 17.17. A. Rougier, C. Lotte, and H. I. Maibach. In vivo relationship between percutaneous absorption and transepidermal water loss. In: R. L. Bronaugh and H. I. Maibach (eds.), Percutaneous Absorption, Marcel Dekker, New York, 1999, pp. 117–132.Google Scholar
- 18.18. V. R. Sinha and M. P. Kaur. Permeation enhancers for transdermal drug delivery. Drug Dev. Ind. Pharm. 26:1131–1140 (2000).Google Scholar